{"id":"NCT01395914","sponsor":"Helsinn Therapeutics (U.S.), Inc","briefTitle":"Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)","officialTitle":"Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2014-06","completion":"2015-02","firstPosted":"2011-07-18","resultsPosted":"2017-07-11","lastUpdate":"2017-09-14"},"enrollment":513,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cachexia","Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Anamorelin HCl","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"100 mg QD","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events","timeFrame":"Over the 12-week treatment period","effectByArm":[{"arm":"Anamorelin HCl","deltaMin":52,"sd":null},{"arm":"Placebo","deltaMin":56,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":72,"countries":["United States","Australia","Belarus","Belgium","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Poland","Russia","Serbia","Slovenia","Spain","Ukraine"]},"refs":{"pmids":["28472437"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":343},"commonTop":["Anaemia","Asthenia","Neutropenia","Decreased appetite"]}}